Journal of Clinical Oncology
Articles in this Issue
Universal solid tumor therapy with CD5-deleted, DSG2-directed CAR-T cells.
2539 Background: CAR-T cell therapy has been curative for many patients with refractory, progressive hematologic cancers, resulting in several FDA approva...
Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.
8046 Background: Perioperative CT + immune checkpoint inhibitor therapy has improved outcomes in resectable NSCLC but most...
Analyzing aberrantly methylated collagen genes in colorectal adenocarcinoma.
e15721 Background: Abnormal methylation, a hallmark of colorectal cancer, interferes with the normal function of genes. By examining methylation patterns...
Safety and efficacy analysis of modified TOPAZ-1: A biweekly regimen of gemcitabine and cisplatin plus monthly durvalumab in advanced biliary tract cancer.
e16265 Background: The pivotal TOPAZ-1 trial established durvalumab plus gemcitabine and cisplatin (GC) as a new first-line standard of care for advanced...
Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
TPS1138 Background: The SV-BR-1-GM breast cancer cell line activates anti-tumor immunity by expressing tumor associated antigens and secreting GM-CSF whic...
Variation in mortality from digestive system cancers in Peru during the period 2001–2020 and its prediction to 2030.
e15689 Background: This study identifies changes in mortality from digestive system cancers in Peru during the period 2001–2020 and predict trends up to 2...
Qualitative findings from providers and patients for planning implementation of screening clinical breast examination in Soweto, South Africa.
1539 Background: Over 50% of South African women with breast cancer (BC) are diagnosed at stages III & IV. To inform an Implementation Mapping process...
Empowering single-cell genomics with scGPT: Precision clustering and genetic insights into acute lymphoblastic leukemia.
e18514 Background: Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by impaired differentiation and abnormal proliferation o...
Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.
2608 Background: Novel combination strategies are being explored to enhance the effectiveness of immune checkpoint inhibitors (ICIs). Prostaglandin E2, th...
Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.
e14609 Background: Serplulimab has demonstrated promising efficacy as a first-line treatment for esophageal squamous cell carcinoma (ESCC) with a combined...
DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.
3000 Background: DB-1310 is a novel ADC comprised of a humanized anti-HER3 IgG1 monoclonal antibody, cleavable peptide lin...
Use of Epic SlicerDicer to assess pregnancy rates in adolescent and young adult patients with breast cancer.
e23353 Background: Adolescent and young adult (AYA) cancer patients represent an underserved population with unique psychosocial and supportive care needs...
Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial.
11061 Background: Anemia in patients (pts) with myelofibrosis (MF) is associated with a significant disease burden, especially in pts who require red bloo...
Trends and disparities in oropharyngeal cancer mortality in the United States: A retrospective analysis of the CDC WONDER database, 1999-2020.
e22555 Background: Oropharyngeal cancers are linked to tobacco, alcohol use, and HPV infection. The 5-year survival rate for oropharyngeal cancer patients...
Envafolimab monotherapy or combination therapy in elderly patients with advanced solid tumors.
e14610 Background: Programmed death-1/programmed death-ligand 1(PD-1/PD-L1) inhibitors have become an important treatment in both monotherapy and combinat...
Risk of myelodysplastic syndrome and myeloproliferative neoplasms in patients with stable coronary artery disease and autoimmune conditions treated with colchicine.
e18581 Background: Patients with stable coronary artery disease (CAD) and autoimmune diseases (AI) are at increased risk of myelodysplastic syndromes (MDS...
Updated analysis from NEJ045A study: Safety and efficacy of durvalumab plus carboplatin and etoposide for previously untreated extensive-stage small-cell lung cancer patients with a poor performance status.
8557 Background: Although the combination of an anti-PD-L1 antibody and platinum-based chemotherapy has become the standard care for extensive-stage small...
Oncologic outcomes of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: A single-center study.
3598 Background: Total neoadjuvant therapy (TNT) reduces the risk of local recurrence and distant metastases in patients (pts) with locally advanced recta...
Health related social needs in an urban academic breast cancer survivorship program.
1636 Background: Health-related social needs (HRSN) impact cancer care and are associated with late stage at diagnosis (dx), prolonged time to therapy ini...
Analyzing trends in multimorbidity-related mortality among patients with cancer and myocardial infarction: A decadal analysis.
10534 Background: Multimorbidity, defined as the coexistence of two or more chronic conditions, poses major challenges to healthcare systems globally. Can...
A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab: JCOG1308C.
2046 Background: Temozolomide (TMZ) is an alkylating agent commonly used as the standard therapy for newly diagnosed glioblastoma (GBM), with the DNA repa...
Evaluating the role of exercise in modulating immunity and immunotherapy outcomes in cancer: A systematic review.
2646 Background: Immunotherapy has become a key cancer treatment, improving survival and reducing side effects. However, its effectiveness can be influenc...
ZNF74 as a novel therapeutic target in melanoma: Unveiling mechanisms and developing precision treatments.
e21606 Background: Melanoma is the most aggressive and fatal skin cancer. Acral melanoma, the predominant subtype in East Asian populations, has a poor pr...
The cost of convenience: Evaluating economic differences in SQ and IV biotherapeutic formulations.
e23163 Background: Subcutaneous (SQ) formulations of anti-neoplastic biotherapeutics provide an alternative to intravenous (IV) administration, offering s...
Durvalumab and tremelimumab combination therapy versus durvalumab monotherapy in metastatic lung cancer: A systematic review and meta-analysis.
e20518 Background: Metastatic lung cancer (mLC) is a leading cause of cancer-related mortality, with limited benefits from standard chemotherapy. Immune c...